Leukotriene modifiers in the treatment of asthma in children (Q37613312)

21 August 2017

1 reference

title

Leukotriene modifiers in the treatment of asthma in children (English)

1 reference

21 August 2017

0 references

Michele Miraglia del Giudice

1

1 reference

21 August 2017

Assunta Pezzulo

2

1 reference

21 August 2017

Carlo Capristo

3

1 reference

21 August 2017

Emilia Alterio

4

1 reference

21 August 2017

Serena Caggiano

5

1 reference

21 August 2017

Diletta de Benedictis

6

1 reference

21 August 2017

Angelo F Capristo

7

1 reference

21 August 2017

12 October 2009

1 reference

Therapeutic advances in respiratory disease

21 August 2017

1 reference

21 August 2017

3

1 reference

21 August 2017

5

1 reference

21 August 2017

245-251

1 reference

Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report.

21 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Mast-cell infiltration of airway smooth muscle in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Hospitalizations with primary versus secondary discharge diagnoses of asthma: implications for pediatric asthma surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Molecular and functional aspects of human cysteinyl leukotriene receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

The expanding role of leukotriene receptor antagonists in chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Leukotriene receptor antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

New insights into the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Leukotriene antagonists and symptom control in chronic persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Inflammatory cells in asthma: mechanisms and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Cysteinyl leukotrienes in asthma: old mediators up to new tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Biopsy markers of airway inflammation and remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Incremental direct expenditure of treating asthma in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Leukotriene-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Urinary leukotriene E4 in preschool children with acute clinical viral wheeze

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

The role of leukotrienes in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Antileukotrienes in the treatment of asthma and allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Short-course montelukast for intermittent asthma in children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Lipoxins and new lipid mediators in the resolution of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Review of recent results of montelukast use as a monotherapy in children with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Montelukast in pediatric asthma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

Airway Inflammation in Childhood Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465809348014

21 January 2018

Identifiers

DOI

10.1177/1753465809348014

1 reference

21 August 2017

1 reference